A Philadelphia jury sent a strong message to Johnson & Johnson regarding the company's marketing of its prescription drug Risperdal. A Maryland man filed a lawsuit alleging that the company failed to properly acknowledge known risks that the prescription medication could lead to breast growth in boys.
A subsidiary of Johnson & Johnson, Ethicon, was hit with a $120 million verdict by a Pennsylvania jury. The lawsuit arose from medical mesh device which was implanted in the plaintiff during a 2008 procedure. The plaintiff, a 68-year-old woman, argued that she suffered from chronic pelvic pain and urinary tract infections as a result of the mesh. She was required to undergo a surgery to remove the mesh. Despite efforts by doctors, the surgery to remove the mesh was unsuccessful, her attorneys stated.